1Hop CE, Tiller PR, Romanyshyn L. In vitro metabolite identification using fast gradient high performance liquid chromatography combined with tandem mass spectrometry [ J ]. Rapid Commun Mass Spectrom,2002; 16:212 -219. 被引量：1
2Lin Z J, Desai - Krieger D, Shum L. Simultaneous determination of glipizide and rosiglitazone unbound drug concentrations in plasma by equilibrium dialysis and liquid chromatography - tandem mass spectrometry [ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2004 ;801:265 - 272. 被引量：1
3Werner AL, Travaglini MT. A review of rosig litazone in type 2 diabetes mellitus[ J]. Pharmacotherapy, 2001 ;21:1082 - 1099. 被引量：1
4Freed MI, Allen A, Jorkasky DK, et al. Systemic exposure to rosiglitazone is unaltered by food [ J ]. Eur J Clin Pharmacol, 1999 ;55:53 - 56. 被引量：1
5Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer,in humans[J]. Drug Metab Dispos ,2000 ;28 : 772 -780. 被引量：1
6Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone[ J]. Br J Clin Pharmacol , 1999 ;48:424 - 32. 被引量：1
7Miller AK, Inglis AL, Thompson K, et al. Effects of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG) [J]. Clin Pharmacol Ther , 1999 ;65:186. 被引量：1
8Chapelsky MC, Thompson K, Miller A, et al. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency [ J ].J Clin Pharmacol, 2003 ;43: 252 - 259. 被引量：1
9Thompson K, Zussman B, Miller A,et al. Pharmacokinetics of rosiglitazone in patients with end - stage renal disease [ J ]. J Int Med Res,2002 ;30:391 - 399. 被引量：1
10Phillips LS, Grunberger G, Miller E, et al. Once - and twice - daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [ J ]. Diabetes Care,2001 ;24: 308 - 315. 被引量：1
